Company / Working Capital
Editas Medicine, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$117.6M
FY2025
5-year range
$117.6M / $460.4M
FY2021-FY2025
Trend
-44.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $460M in FY2021 to $118M in FY2025.
Based on SEC 10-K filings.
$118M in FY2025 with a 5-year CAGR of -20.1%.
Declined from $278M to $118M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -26.5%
- 5-Year CAGR
- -20.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Editas Medicine, Inc.'s working capital has declined for 4 consecutive years.
- 5-year CAGR of -20.1%, indicating a declining trend.
- In FY2025, working capital decreased 44.5% year-over-year.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.6M | -44.5% |
| FY2024 | $212.1M | -23.6% |
| FY2023 | $277.6M | -6.4% |
| FY2022 | $296.6M | -35.6% |
| FY2021 | $460.4M | +27.6% |
| FY2020 | $360.9M | -10.6% |
| FY2019 | $403.9M | +19.2% |
| FY2018 | $338.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026